Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.
Patients who received intravesical BCG instillation following surgery for nonmuscle-invasive bladder cancer had a lower risk of recurrence of upper tract urothelial carcinoma and bladder cancer, a study found.